TKPHF
TAKEDA PHARMACEUTICAL CO LTD
$31.30
+2.72%
No data for this timeframe.
Vol
SEC Reports10
Recent Activity
Jun 9, 2026
SEC
Takeda announced the issuance of 16,989,076 ordinary shares (10,892,917 new shares and 6,096,159 treasury shares) at ¥5,
6-K — Impact 3/10
Jun 5, 2026
SEC
Takeda discloses that a May 18, 2026 jury verdict in the AMITIZA antitrust litigation constitutes an adjusting subsequen
6-K — Impact 6/10
Jun 5, 2026
SEC
Takeda revised its FY2025 consolidated financial statements to recognize a provision for legal proceedings following an
6-K — Impact 6/10
Analyst Ratings
5Strong Buy
8Buy
6Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
10 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 2 mixed, 4 neutral. Avg impact: 5.0/10.
NEUTRAL
6-K
3/10
Takeda announced the issuance of 16,989,076 ordinary shares (10,892,917 new shares and 6,096,159 tre
Jun 9, 2026
BEARISH
6-K
6/10
Takeda discloses that a May 18, 2026 jury verdict in the AMITIZA antitrust litigation constitutes an
Jun 5, 2026
BEARISH
6-K
6/10
Takeda revised its FY2025 consolidated financial statements to recognize a provision for legal proce
Jun 5, 2026
BEARISH
6-K
6/10
Takeda reported FY2025 (year ended March 31, 2026) results showing a net loss attributable to owners
Jun 5, 2026
NEUTRAL
6-K
2/10
Takeda filed a shelf registration in Japan for up to JPY 240 billion to issue shares under its Long
Jun 1, 2026
MIXED
6-K
6/10
Takeda filed its Notice of Convocation for the 150th Annual General Meeting of Shareholders, which i
May 26, 2026
NEUTRAL
6-K
5/10
Takeda filed its annual report (FY ended March 31, 2026) via Form 6-K, disclosing total revenue of J
May 26, 2026
MIXED
6-K
6/10
Takeda filed a 6-K containing its executive compensation overview and a shareholder letter from CEO-
May 26, 2026
BEARISH
6-K
8/10
A U.S. federal jury returned a verdict against Takeda in the AMITIZA (lubiprostone) antitrust litiga
May 19, 2026
NEUTRAL
6-K
2/10
Takeda filed a 6-K announcing the continuation of its stock compensation plan for directors and stoc
May 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 68% buy across 19 analysts — 5 strong buy, 8 buy, 6 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1161.5B | 5.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1165.1B | 4.7% | — |
| Current FY 2027-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $4620.5B | 681.0% | — |
| Next FY 2028-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $4692.9B | 1.6% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| May 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| Apr 1, 2026 | 3 | 8 | 8 | 0 | 0 | 58% | |
| Mar 1, 2026 | 3 | 8 | 8 | 0 | 0 | 58% | |
| Feb 1, 2026 | 3 | 8 | 8 | 0 | 0 | 58% | |
| Jan 1, 2026 | 3 | 7 | 8 | 0 | 0 | 56% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.